It’s a tough market but definitely a space if PYC can show they can improve delivery in 2019. ASO’s have had the world of promise for the last 30 years and plenty if big deals between Ionis & big pharma over the last 10 years but very few actually resulting in approved drugs in market. Formiverson 20 years ago only lasted less less than 2 years after FDA approval before it was outcompeted and pulled from shelf. Genzyme (Sanofi) and Ionis had largest bio deal of the year in 2008 with well over a billion for Kynamro - eventually contraversial approval but made no money sanofi wiped their hands and ionis sold it off to Kastle for $50m. Sarepta Exondys knocked back by FDA review board but eventually a controversial approval yet still stuck with EMA in Europe seeking approval. Biogen & Ionis with Spiranza winning FDA approval last year - not sure how much of that was weighted in there being no drugs at all for SMA ? But it’s got a ripper price tag on it $300k ?
Tough market but you’d think if they can improve it definitely opens things up.
PYC Price at posting:
2.9¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)